Association of combined PD-L1 expression and tumor-infiltrating lymphocytes features with survival and treatment outcomes in patients with metastatic melanoma

Source: Genoweb, November 2019

NEW YORK – Taiwanese cancer diagnostic firm ACT Genomics said on Monday that it has launched a study in collaboration with the University of California, San Diego Moores Cancer Center that will evaluate gene expression signals associated with the tumor microenvironment that may predict outcome in melanoma patients treated with PD-1 inhibition.

The partners will analyze samples from 100 melanoma patients using a chip-based multiplex qPCR assay that characterizes the expression of 92 immune-related genes associated with things like antigen presentation machinery, immune checkpoints, specific immune cell populations, and cell signaling in the tumor microenvironment.

The proprietary test, called ACTTME, was designed by ACT Genomics to provide a cost-effective tool to guide precision use of immune-checkpoint inhibitors.

Read the original full article